Update On Scheme Of Arrangement Involving Brooks Steriscience Limited ('BSL'), A Joint Venture / Associate Of The Company.
BROOKS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Brooks Steriscience Limited (BSL), a joint venture/associate of Brooks Laboratories, has received a No-Objection/No Adverse Observation letter from NSE and BSE for its composite scheme of arrangement and amalgamation (merger by absorption). The scheme involves Steriscience Specialties Private Limited, BSL, Steriscience Pte. Limited, Strides Pharma Services Private Limited, and Onesource Specialty Pharma Limited. The stock exchange approval is valid for 6 months. However, the Board of BSL has decided to carry out a further review before filing the scheme with the National Company Law Tribunal (NCLT), to be completed within this 6-month window.
This is a procedural update at the JV/associate level and has limited direct impact on Brooks Labs shareholders. Progress is positive (stock exchanges have cleared the scheme), but the deal still needs NCLT approval and NCLT filing has not yet happened, so uncertainty remains.